What if clinical trials were designed to support the test of several compounds at the same time in any disease area instead of focusing on a single compound every time a trial is run?
What if patients had a steady voice in the outline of clinical trials which would consistently incorporate their inputs and outcomes?
What if a single control group could sustain multi-compound trials hence, increasing the patients’ chances of receiving a potentially effective new treatment during the clinical trial?
What if pharmaceutical companies were to collaborate instead of running parallel trials on similar compounds as sometimes occurs?
What if clinicians, researchers, patients, regulators and the industry shared their knowledge and created a forum that promoted open debate on clinical trials and drug development?
Why if a new paradigm of clinical trials was to provide speedier access to more effective and personalised medicines whilst keeping operational costs under control?
The EU funded EU-PEARL aims to provide positive answers to all these questions by embracing technological innovation, health data management and a ground-breaking collaborative approach.
Clinical research on Oncology, Alzheimer’s diseases or ALS are already focusing on multi-compound trials which allow to test several drugs simultaneously, often against a single control group. EU-PEARL intends to build on the positive impact that building a patient centric, cross-company, multi-drug framework suitable for any disease would have on clinical research.
Page under construction
Improving health outcomes for patients by promoting a new paradigm of clinical trials is at the core of EU-PEARL. This innovative approach to clinical research and drug development aims to deliver substantial benefits in the long run, not only for patients, clinicians or the industry, but to society as a whole.
Primarily, EU-PEARL’s will have an expected positive impact on: